Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Verstovšek, Srđan; Gotlib, Jason; A. Mesa, Ruben; M. Vannucchi, Alessandro; Kiladjian, Jean‐Jacques; Cervantes, Francisco; Harrison, Claire; Paquette, Ronald; Sun, William; Naim, Ahmad; Langmuir, Peter; Dong, Tuochuan; Gopalakrishna, Prashanth; Gupta, Vikas

doi:10.1186/s13045-017-0527-7

Public

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Published in Journal of Hematology & Oncology • Sep 29, 2017

Authors:

Srđan Verstovšek

Jason Gotlib

Ruben A. Mesa

Abstract

BACKGROUND: Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, in patients with intermediate-2 (int-2) or h...

Subject

Ruxolitinib

Medicine

Myelofibrosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!